{"nctId":"NCT01199705","briefTitle":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","startDateStruct":{"date":"2010-09"},"conditions":["Primary Immune Deficiency"],"count":25,"armGroups":[{"label":"IgPro20","type":"EXPERIMENTAL","interventionNames":["Biological: Immune Globulin Subcutaneous (Human) (SCIG)"]}],"interventions":[{"name":"Immune Globulin Subcutaneous (Human) (SCIG)","otherNames":["Hizentra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of PID with hypo- or agammaglobulinemia requiring IgG replacement therapy\n* Intravenous IgG (IVIG) therapy at regular 3- or 4-week intervals at a stable dose for at least 3 doses prior to signing of informed consent\n* Written informed consent\n\nExclusion Criteria:\n\n* Newly diagnosed PID, i.e., subjects who have not previously received immunoglobulin replacement therapy\n* Ongoing serious bacterial infections (SBIs: pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of screening\n* Ongoing or history of concomitant malignancies of lymphoid cells such as lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma\n* Allergic or other severe reactions to immunoglobulins or other blood products recorded in the past 3 months or at the time of screening\n* Pregnancy or nursing mother\n* A positive result at screening on any of the following viral markers: human immunodeficiency virus-1 (HIV-1), HIV-2, hepatitis C virus, or hepatitis B virus\n* Participation in a study with other investigational product during this study and within 3 months prior to screening\n* Subjects who donated blood (200 mL within one month or 400 mL within 3 months prior to screening), or planning to donate blood during the study","healthyVolunteers":false,"sex":"ALL","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"IgG Trough Level","description":"Geometric means of trough levels measured before 3 intravenous immunoglobulin (IVIG) infusions was compared with those of trough levels measured at steady-state for 3 subcutaneous immunoglobulin (SCIG) infusions (weeks 16, 20 and 24). The ratio of these geometric means was the primary outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":null},{"groupId":"OG001","value":"1.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Infection Episodes (Serious and Non-serious) by Study Period","description":"Number of infection episodes (serious and non-serious) presented by study period:\n\n* IVIG treatment: Study subjects were treated with their IVIG therapy with 3- or 4-weekly schedules for 3 dosing cycles (9 to 12 weeks; before being switched to SCIG treatment with IgPro20).\n* SCIG treatment (wash-in/wash-out; weeks 1 to 12): IgPro20 was administered subcutaneously with the first subcutaneous (SC) IgPro20 infusion starting 1 week after the last IVIG dose. Subjects were treated with weekly SC IgPro20 infusions for a 12-week wash-in/wash-out period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy.\n* SCIG treatment (efficacy; weeks 13 to 24): After the SCIG wash-in/wash-out treatment, subjects were treated with weekly SC IgPro20 infusions for a 12-week efficacy period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Infection Episodes (Serious and Non-serious) by Study Period, PPS Population","description":"The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days.\n\nStudy periods:\n\n* IVIG treatment (up to 12 weeks)\n* SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks)\n* SCIG IgPro20 treatment (efficacy) (12 weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":null},{"groupId":"OG001","value":"5.79","spread":null},{"groupId":"OG002","value":"2.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Infection Episodes (Serious and Non-serious) by Study Period, FAS Population","description":"The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days.\n\nStudy periods:\n\n* IVIG treatment (up to 12 weeks)\n* SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks)\n* SCIG IgPro20 treatment (efficacy) (12 weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.75","spread":null},{"groupId":"OG001","value":"5.79","spread":null},{"groupId":"OG002","value":"3.14","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Annualized Rate of Serious Bacterial Infections (SBIs), PPS Population","description":"The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days.\n\nStudy periods:\n\n* IVIG treatment (up to 12 weeks)\n* SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks)\n* SCIG IgPro20 treatment (efficacy; 12 weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections by Study Period","description":"Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Annualized Rate of Serious Bacterial Infections (SBIs), FAS Population","description":"The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days.\n\nStudy periods:\n\n* IVIG treatment (up to 12 weeks)\n* SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks)\n* SCIG IgPro20 treatment (efficacy; 12 weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Hospitalization Due to Infections by Study Period","description":"Median number of days of hospitalization due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Use of Antibiotics for Infection Prophylaxis and Treatment","description":"Median number of days of use of antibiotics for infection prophylaxis and/or treatment, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null},{"groupId":"OG001","value":"48.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of All Adverse Events by Relatedness and Seriousness","description":"The rate of adverse events (AEs) was the number of treatment-emergent AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.653","spread":null},{"groupId":"OG001","value":"0.457","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":null},{"groupId":"OG001","value":"0.296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.002","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Mild, Moderate, or Severe Local Reactions","description":"In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of: infusion site discomfort, infusion site erythema, infusion site haemorrhage, infusion site induration, infusion site inflammation, infusion site pain, infusion site pruritus, infusion site swelling, injection site erythema, injection site extravasation, injection site induration, injection site irritation, injection site pain, injection site pruritus, injection site swelling, and puncture site reaction.\n\nMild AE: Symptoms are easily tolerated and there is no interference with daily activities; Moderate AE: Discomfort enough to cause some interference with daily activities; Severe AE: Incapacitating with inability to work or do usual activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.274","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Local reactions","Nasopharyngitis","Upper respiratory tract infection","Influenza","Dental caries"]}}}